Expert Panel Discussion on Metastatic Breast Cancer (MBC)

المقدمة

سجل الان

Dr. Ahmed Refae, Dr. Omalkhair Abulkhair, Dr. Meteb Al-Foheidi, Dr. Abdullah Altwairgi, and Dr. Esam Murshid discuss the implications of the Overall Survival (OS) data of CDK 4 & 6 Inhibitors on patients management in clinical practice.

الأهداف

To discuss and share:
1. The Overall Survival data of CDK 4 & 6 inhibitors
2. HR+ HER2- MBC patients with less favorable prognosis management
3. CDK 4 & 6 inhibitors adverse event management